Moleculin Biotech Stock Forecast for 2023 - 2025 - 2030
Updated on 05/20/2024
Moleculin Biotech Stock Forecast and Price Target
Given the average yearlong price target of $40.00 provided by prominent analysts over the past few months, there is a potential upside of approximately 687.4% from the last closing price in May, 2024 for Moleculin Biotech's stock if it is reached. This estimation is based on a high estimate of $45.00 and a low estimate of $20.00. If you are interested in MBRX stock, you should also look at its competitors.
687.40% Upside
Moleculin Biotech Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Moleculin Biotech's Price has grown, moving from $0.00 to $0.00 – an increase of 100.00%. In the next year, analysts predict that Fair Value will jump to $5.43 – up 100.00% from the current level. Looking ahead to seven years, experts forecast that Fair Value will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$166.42 | Buy/Sell | $178.42 | 9.66% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$312.47 | Buy/Sell | $303.65 | 2.41% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$67.72 | Buy/Sell | $87.82 | 18.13% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$230.57 | Buy/Sell | $299.62 | 25.12% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$77.56 | Buy/Sell | $111.56 | 42.47% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$57.10 | Buy/Sell | $77.05 | 37.48% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$67.00 | Buy/Sell | $34.00 | 71.64% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$104.96 | Buy/Sell | $85.71 | 14.33% |
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$10.24 | Buy/Sell | $20.42 | 144.14% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| CBAY Stock Forecast | CymaBay Therapeutics | Hold |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$24.77 | Buy/Sell | $52.00 | 122.04% |
Moleculin Biotech EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, EBITDA for Moleculin Biotech has grown by 50.97%, going from $-19.54M to $-29.50M. According to 1 analysts, Moleculin Biotech's EBITDA will fall by 5.08% in the next year, reaching $-28.00M. Professionals believe that By 2030, Moleculin Biotech's EBITDA will fall to $79.00M – a 367.80% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$9.57 | Buy/Sell | $17.90 | 88.09% |
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$38.21 | Buy/Sell | $63.29 | 85.82% |
Moleculin Biotech EBIT Forecast for 2023 - 2025 - 2030
Moleculin Biotech's EBIT has grown in the last three years, jumping from $-19.74M to $-29.63M – an increase of 50.10%. In the next year, analysts predict that EBIT will reach $-31.59M – an increase of 6.61%. In 2030, professionals predict that Moleculin Biotech's EBIT will decrease by 842.12%, to $219.89M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$14.79 | Buy/Sell | $33.78 | 89.32% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$48.35 | Buy/Sell | $42.58 | 15.82% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$9.21 | Buy/Sell | $6.00 | 8.58% |
Moleculin Biotech EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Moleculin Biotech's EPS has grown, moving from $-2.00 to $0.00 – an increase of 100.00%. In the next year, analysts predict that EPS will jump to $-0.92 – up 100.00% from the current level. Looking ahead to seven years, experts forecast that EPS will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$7.81 | Buy/Sell | $9.94 | 79.26% |
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$34.34 | Buy/Sell | $40.00 | 29.59% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.11 | Buy/Sell | $25.00 | 125.02% |
.jpg)